Table 1 Patients’ demographic and risk factor characteristics
HC (n = 72) | CP (n = 120) | IAS (n = 108) | PΔ | P# | P * | |
|---|---|---|---|---|---|---|
Age, mean ± SD | 56.0 ± 10.2 | 56.9 ± 7.6 | 61.5 ± 12.1 | 0.652 | 0.132 | 0.281 |
Gender (female), n (%) | 28 (38.9) | 48 (40.0) | 48 (44.4) | 0.879 | 0.460 | 0.497 |
BMI, Kg/m2 | 24.2 ± 4.2 | 26.1 ± 8.6 | 26.9 ± 8.9 | 0.035 | 0.031 | 0.756 |
sBP, mmHg | 123.2 ± 17.7 | 134.1 ± 16.54 | 138.1 ± 18.72 | 0.065 | 0.036 | 0.452 |
dBP, mmHg | 81.6 ± 10.1 | 83.52 ± 12.05 | 85.6 ± 10.1 | 0.396 | 0.041 | 0.462 |
TG, mmol/l | 1.325 ± 0.35 | 1.446 ± 0.77 | 1.504 ± 0.83 | 0.689 | 0.478 | 0.837 |
TC, mmol/l | 3.935 ± 0.93 | 4.078 ± 0.68 | 4.697 ± 0.85 | 0.696 | 0.019 | 0.089 |
HDL, mmol/l | 1.198 ± 0.26 | 1.05 ± 0.16 | 0.955 ± 0.15 | 0.099 | 0.003 | 0.297 |
LDL, mmol/l | 2.43 ± 0.81 | 2.626 ± 0.55 | 2.624 ± 0.78 | 0.623 | 0.601 | 0.991 |
Glu, mmol/l | 5.75 ± 1.06 | 6.059 ± 3.32 | 5.58 ± 0.97 | 0.745 | 0.748 | 0.555 |
CRP, mg/l | 0.65 (0.31-1.37) | 1.55 (0.65-2.71) | 2.75(1.2-3.25) | 0.021 | <0.001 | 0.012 |
Hypertension, n (%) | 0 | 30 (25.0) | 84 (77.8) | - | - | <0.001 |
cEPCs (%) | ||||||
CD34+ | 0.293 ± 0.182 | 0.364 ± 0.201 | 0.553 ± 0.311 | 0.028 | 0.009 | 0.019 |
CD34+/CD133+ | 0.098 ± 0.032 | 0.113 ± 0.064 | 0.246 ± 0.142 | 0.382 | <0.001 | <0.001 |
CD34+/CD133+/KDR+ | 0.021 ± 0.011 | 0.026 ± 0.012 | 0.059 ± 0.031 | 0.401 | <0.001 | <0.001 |
Diabetes, n (%) | 0 | 6 (5.0) | 24 (22.2) | - | - | <0.001 |
Hyperlipidemia, n (%) | 0 | 18 (15.0) | 24 (22.2) | - | - | 0.160 |
CAD, n (%) | 0 | 12 (10.0) | 18 (16.7) | - | - | 0.137 |
Smoking, n (%) | 0 | 48 (40.0) | 78 (72.2) | - | - | <0.001 |
Drug treatment | - | - | ||||
Statin, n (%) | 4 (5) | 31 (26) | 35 (32) | - | - | 0.316 |
ACE inhibitor, n (%) | - | 20 (17) | 31 (29) | - | - | 0.029 |
Angiotensin II receptor blocker, n (%) | - | 3 (2) | 2 (2) | - | - | 0.739 |
Beta blocker, n (%) | - | 10 (8) | 13 (12) | - | - | 0.345 |
Calcium antagonist, n (%) | - | 19 (16) | 34 (32) | - | - | 0.005 |